Firefly Neuroscience (AIFF) EBITDA (2010 - 2026)

Firefly Neuroscience has reported EBITDA for 16 years, with the latest figure at -$2.0 million in Q2 2026.

• On a quarterly basis, EBITDA fell 20.81% year-over-year to -$2.0 million in Q2 2026; TTM through Jun 2026 was -$9.1 million, a 27.84% increase from a year earlier, with the FY2025 full-year figure at -$8.9 million, up 11.92% from the prior year.
• EBITDA was -$2.0 million for Q2 2026 at Firefly Neuroscience, up from -$2.0 million in the prior quarter.
• The five-year high for EBITDA was $493116.0 in Q2 2023, with the low at -$6.6 million in Q3 2024.
• Average EBITDA over 5 years is -$1.8 million, with a median of -$1.6 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 3062.76% in 2022, then soared 130.83% in 2023.
• Over 5 years, EBITDA stood at -$1.0 million in 2022, then tumbled by 54.76% to -$1.6 million in 2023, then plunged by 322.34% to -$6.6 million in 2024, then soared by 62.21% to -$2.5 million in 2025, then rose by 21.07% to -$2.0 million in 2026.
• The last three EBITDA figures came in at -$2.0 million (Q2 2026), -$2.0 million (Q1 2026), and -$2.5 million (Q4 2025), per Business Quant data.